#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA4145311	B	Displacement of [3H]-diprenorphine from human DOR expressed in CHO cell membranes after 80 mins by scintillation counting analysis	Homo sapiens	8		cell-based format	Scientific Literature
2.	ALA4145312	B	Displacement of [3H]-diprenorphine from human MOR expressed in CHO cell membranes after 80 mins by scintillation counting analysis	Homo sapiens	7		cell-based format	Scientific Literature
3.	ALA4145313	B	Displacement of [3H]-diprenorphine from human mu-delta opioid receptor heterodimer expressed in CHO cell membranes at high site fraction after 80 mins by scintillation counting analysis relative to control	Homo sapiens	9		cell-based format	Scientific Literature
4.	ALA4145314	B	Displacement of [3H]-diprenorphine from human mu-delta opioid receptor expressed in CHO cell membranes after 80 mins by scintillation counting analysis	Homo sapiens	9		cell-based format	Scientific Literature
5.	ALA4145315	F	Antagonist activity at human MOR expressed in CHO cell membranes mixed with human DOR expressed in CHO cell membranes assessed as inhibition of CYM51010-induced [35S]-GTPgammaS binding preincubated for 5 mins followed by CYM51010 and [35S]-GTPgammaS addition measured after 80 mins	Homo sapiens	1		cell-based format	Scientific Literature
6.	ALA4145316	B	Selectivity ratio of KiH for human mu-delta opioid receptor heterodimer expressed in CHO cell membranes to Ki for human DOR expressed in CHO cell membranes	Homo sapiens	6		cell-based format	Scientific Literature
7.	ALA4145317	F	Antagonist activity at human mu-delta opioid receptor heterodimer expressed in CHO cell membranes assessed as inhibition of CYM51010-induced [35S]-GTPgammaS binding at high site fraction preincubated for 5 mins followed by CYM51010 and [35S]-GTPgammaS addition measured after 80 mins	Homo sapiens	9		cell-based format	Scientific Literature
8.	ALA4145318	F	Antagonist activity at human mu-delta opioid receptor heterodimer expressed in CHO cell membranes assessed as inhibition of CYM51010-induced [35S]-GTPgammaS binding at high site fraction preincubated for 5 mins followed by CYM51010 and [35S]-GTPgammaS addition measured after 80 mins relative to control	Homo sapiens	8		cell-based format	Scientific Literature
9.	ALA4145319	F	Antagonist activity at human DOR expressed in CHO cell membranes assessed as inhibition of CYM51010-induced [35S]-GTPgammaS binding preincubated for 5 mins followed by CYM51010 and [35S]-GTPgammaS addition measured after 80 mins	Homo sapiens	8		cell-based format	Scientific Literature
10.	ALA4145320	F	Antagonist activity at human MOR expressed in CHO cell membranes assessed as inhibition of CYM51010-induced [35S]-GTPgammaS binding preincubated for 5 mins followed by CYM51010 and [35S]-GTPgammaS addition measured after 80 mins	Homo sapiens	8		cell-based format	Scientific Literature
11.	ALA4145321	B	Selectivity ratio of IC50H for human mu-delta opioid receptor heterodimer expressed in CHO cell membranes to IC50 for human DOR expressed in CHO cell membranes	Homo sapiens	6		cell-based format	Scientific Literature
12.	ALA4145322	F	Antagonist activity at human mu-delta opioid receptor heterodimer expressed in CHO cell membranes assessed as inhibition of DAMGO-induced [35S]-GTPgammaS binding preincubated for 5 mins followed by DAMGO and [35S]-GTPgammaS addition measured after 80 mins	Homo sapiens	3		cell-based format	Scientific Literature
13.	ALA4145323	F	Antagonist activity at human KOR expressed in CHO cell membranes assessed as inhibition of U50488-induced [35S]-GTPgammaS binding preincubated for 5 mins followed by U50488 and [35S]-GTPgammaS addition measured after 80 mins	Homo sapiens	4		cell-based format	Scientific Literature
14.	ALA4145324	F	Antinociceptive activity in icv dosed CD1 mouse assessed as reduction in CYM51010-induced nociception pretreated for 5 mins followed by CYM51010 injection measured up to 2 hrs by tail flick assay	Mus musculus	1		organism-based format	Scientific Literature
15.	ALA4145325	F	Antinociceptive activity in icv dosed CD1 mouse assessed as reduction in Deltorphin-2-induced nociception pretreated for 5 mins followed by Deltorphin-2 injection measured up to 2 hrs by tail flick assay	Mus musculus	1		organism-based format	Scientific Literature
16.	ALA4145326	F	Antinociceptive activity in CD1 mouse assessed as reduction in DAMGO-induced nociception up to10 nmol, icv pretreated for 5 mins followed by DAMGO injection measured up to 2 hrs by tail flick assay	Mus musculus	1		organism-based format	Scientific Literature
17.	ALA4145327	F	Antinociceptive activity in CD1 mouse assessed as reduction in DSLET-induced nociception up to 10 nmol, icv pretreated for 5 mins followed by DSLET injection measured up to 2 hrs by tail flick assay	Mus musculus	1		organism-based format	Scientific Literature
18.	ALA4145329	F	Antinociceptive activity in CD1 mouse assessed as reduction in morphine-induced nociception at 10 nmol pretreated for 5 mins followed by morphine injection measured up to 2 hrs by tail flick assay	Mus musculus	1		organism-based format	Scientific Literature
19.	ALA4145330	F	Antinociceptive activity in CD1 mouse assessed as reduction in SNC80-induced nociception at 10 nmol pretreated for 5 mins followed by SNC80 injection measured up to 2 hrs by tail flick assay	Mus musculus	1		organism-based format	Scientific Literature
20.	ALA4145331	F	Reduction in morphine dependence expression in acute morphine dependence ICR mouse model assessed as inhibition of naloxone-precipitated jumping behavior at 1 nmol, icv administered 5 mins prior to naloxone injection measured up to 20 mins relative to control	Mus musculus	1		organism-based format	Scientific Literature